In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina. Clinical trials have demonstrated the efficacy of this drug, especially when treatment is begun soon after the initial event. The antiplatelet actions of aspirin seem to be the most plausible explanation for its efficacy in reducing mortality and the rate of reinfarction. A single daily 325-mg tablet is effective and produces side-effect incidences of only zero to two percent above those produced by placebo. This article assesses the current state of knowledge regarding the value of aspirin therapy in survivors of acute MI and the implications for clinical practice.
DegaetanoGCerlettiCDejanaELatiniR. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation1985; 72: 1185–93.
2.
ElwoodPCCochraneALBurrML. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J1974; 1: 436–40.
3.
The Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chronic Dis1976; 29: 625–42.
4.
BreddinKLoewDLechnerKOberlaKWalterE. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation1980; 62 (suppl V): 63–72.
5.
ElwoodPCSweetnamPM. Aspirin and secondary mortality after myocardial infarction. Lancet1979; 2: 1313–5.
6.
Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA1980; 243: 661–9.
7.
Persantine-Aspirin Reinfarction Study Research Group. Persantine-aspirin reinfarction study. Circulation1980; 62 (suppl II): 1–22.
8.
CravenLL. Experiences with aspirin (acetylsalicylic acid) in nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J1953; 75: 38–44.
9.
Boston Collaborative Drug Surveillance Group. Regular aspirin use and myocardial infarction. Br Med J1974; 1: 440–3.
10.
RosenbergFJGimber-PhillipsPEGroblewskiGE. Acetylsalicylic acid: inhibition of platelet aggregation in the rabbit. J Pharmacol Exp Ther1971; 179: 410–8.
11.
JohnstonOLLiuPRosenBR. In vivo detection of reperfused myocardium by nuclear magnetic resonance imaging. J Am Coll Cardiol1987; 9: 127–35.
12.
JhawarBKTrivediHHBhargavaRKMisraNP. Preliminary study of effect of aspirin and dipyridamole on platelet adhesiveness and fibrinolytic activity in acute myocardial infarction. J Assoc Phys India1978; 26: 805–9.
13.
OlivaPB. Pathophysiology of acute myocardial infarction. Ann Intern Med1981; 94: 236–50.
14.
MayGSEberleinKAFurbergCDPassamaniERDemetsDL. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis1982; 24: 331–52.
15.
ChahineRA. Unstable angina. The problem of definition. Br Heart J1975; 36: 1246–9.
KusterLJFrolichJC. Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet activating factor following low dose acetylsalicylic acid in man. Prostaglandins1986; 32: 415–23.
18.
Aspirin: What dose? (editorial)Lancet1986; 1: 592–3.
19.
WekslerBB. Prostaglandins and vascular function. Circulation1984; 70 (suppl III): 63–71.
20.
ElwoodPC. Aspirin in the prevention of myocardial infarction. Drugs1984; 28: 1–5.
21.
MehtaJLMehtaPLopezLOstrowskiNAguilaE. Platelet function and biosynthesis of prostacyclin and thromboxane A2 in whole blood after aspirin administration in human subjects. J Am Coll Cardiol1984; 4: 806–11.
22.
KeltonJGHirshJCarterCJBuchananMR. Thrombogenic effect of high dose aspirin in rabbits: relationship to inhibition of vessel wall synthesis of PGI2-like activity. J Clin Invest1978; 62: 892–5.
23.
HirshJ. The optimal antithrombotic dose of aspirin (editorial). Arch Intern Med1985; 145: 1582–3.
24.
FitzgeraldGABrashAROatesJAPedersonAK. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthetase in man. J Clin Invest1983; 71: 1336–43.
25.
LewisHDDavisJWArchibaldDG. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med1983; 309: 396–403.
26.
DefreynGDeckmynHVermylenJ. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thrombos Res1982; 26: 389–400.
27.
PedersenAKFitzgeraldGA. The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action. Circulation1985; 72: 1164–76.
28.
O'BrienJRShuttleworthRDEtheringtonMDAdamsC. Correlations between platelet ‘function’ tests and a comparison of indobufen and aspirin. Curr Ther Res1983; 34: 415–22.
29.
CrutchleyDJRyanUSRyanJW. Effect of aspirin and dipyridamole on the degradation of adenosine diphosphate by cultured cells derived from bovine pulmonary artery. J Clin Invest1980; 66: 29–35.
30.
HenriksenTMahoneyEMSteinbergD. Interactions of plasma lipoproteins with endothelial cells. Ann NY Acad Sci1982; 401: 102–6.
31.
RawlingsCAKeithJCSchaubRG. Effect of acetylsalicylic acid on pulmonary arteriosclerosis induced by a one-year Dirofilaria immitis infection. Arteriosclerosis1985; 5: 355–65.
32.
PickRChediakJClickG. Aspirin inhibits development of coronary atherosclerosis in cynomolgus monkeys (Macaca fascicularis) fed an atherogenic diet. J Clin Invest1979; 63: 158–62.
33.
HessHMeitaschkADeichselG. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet1985; 1: 415–19.
34.
SommarivaD. Effects of acetylsalicylic acid on plasma lipids and on post-heparin lipase activities. Int J Clin Pharmacol Ther Toxicol1981; 19: 112–6.
35.
BraunwaldEFriedwaldWTFurbergCT. Proceedings of the workshop on platelet-active drugs in the secondary prevention of cardiovascular events. Circulation1980; 62 (suppl V): 126–35.
36.
Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation1980; 62: 449–61.
37.
KlimtCRKnatterudGLStamlerJMeierP. Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol1986; 7: 251–69.
38.
McKennaRGalanteJBachmannF. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J1980; 1: 514–7.
39.
BreddinKLoewDLechnerKOberlaKWalterE. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Hemostasis1980; 9: 325–44.
40.
BorhaniNO. Prevention of coronary disease in practice. Implications of the results of recent clinical trials. JAMA1985; 254: 257–62.
41.
LewisHD. Unstable angina: status of aspirin and other forms of therapy (abstract). Circulation1985: 72 (suppl): V-155.
42.
CairnsJGentMSingerJ. A study of aspirin and/or sulfinpyrazone in unstable angina (abstract). Circulation1984; 70 (suppl 2) II: 415.
43.
CairnsJAGentMSingerJ. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med1985; 313: 1369–75.
44.
American-Canadian Co-operative Study Group. Persantine-aspirin trial in cerebral ischemia. Part II: endpoint results. Stroke1985; 16: 406–15.
45.
NagatsukaKUyamaONakabayashiSYonedaSKimmaKKamuraT. A new approach to antithrombotic therapy—evaluation of combined therapy of thromboxane synthetase inhibitor and a very low dose of aspirin. Stroke1985; 16: 806–9.
46.
KnaterudGI. Strong indication beta blockers enhance post-MI benefits of persantine and aspirin (editorial). Int Med News1985; 18: 65.
47.
RosenbergLSloneDShapiroSKaumanDWMiettinenOSStolleyPD. Aspirin and myocardial infarction in young women. Am J Public Health1982; 72: 389–91.
GodfreyPPBochnerFGrahame-SmithDG. Dose-dependent inhibition of phosphoinositide metabolism in human platelets in vitro and in vivo. Br J Clin Pharm1986; 22: 443–7.
50.
CerlettiCCarrieroMRDegaetanoG. Platelet aggregation response to single or paired aggregating stimuli after low-dose aspirin. N Engl J Med1986; 314: 316–8.
51.
Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med1978; 299: 53–9.
52.
HarrisWHSalzmanEWAthanasoulisCA. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med1977; 297: 1246–9.
53.
HirshJ. Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction. Arch Intern Med1981; 141: 311–5.
54.
FrishmanWHFurbergCDFriedewallWT. β-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med1984; 310: 830–7.
55.
CairnsJAFieldsWSKleinM. Aspirin prophylaxis for angina, MI and stroke: assessment of benefit. Modern Med1986; 54: 157–9.
56.
1984 report of the Joint National Committee on Detection, Evaluation, Treatment of High Blood Pressure. Washington, DC: National Institutes of Health, Department of Health and Human Services and United States Public Health Service.
57.
The E.P.S.I.M. Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med1982; 307: 701–8.
58.
DegaetanoGDBucchiFGambinoMCCerlettiC. Does oral aspirin spare the kidney-? (letter)Lancet1986; 1: 736.
59.
WilsonTWMcCauleyFAWellsHD. Effects of low-dose aspirin on responses to furosemide. J Clin Pharmacol1986; 26: 100–5.
60.
FlowerRJMoncadaSVaneJR. Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: GilmanAGGoodmanLSGilmanA, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed.New York: Macmillan, 1980: 682–728.
61.
CokerSJParrattJR. Aspirin in the early stages of myocardial infarction. In: L'EtangHJC, ed. Aspirin symposium 1983. London: Royal Society of Medicine, 1984: 236–50.
62.
DegaetanoGCerlettiCDejanaEVermylenJ. Current issues in thrombosis prevention with antiplatelet drugs. Drugs1986; 31: 517–49.
